Trial Profile
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs YE-NEO-001 (Primary)
- Indications HER2 negative breast cancer; HER2 positive breast cancer; Liver cancer; Malignant melanoma; Pancreatic cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- Acronyms QUILT-2.025 NANT
- Sponsors NantBioScience
- 22 Jun 2023 Planned End Date changed from 30 Dec 2020 to 30 Dec 2025.
- 22 Jun 2023 Planned primary completion date changed from 30 Dec 2019 to 15 Jul 2025.
- 22 Jun 2023 Status changed from recruiting to active, no longer recruiting.